NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it will provide MGMT gene promoter methylation testing services for Merck KGaA’s clinical trial program for cilengitide, a drug being developed for glioblastoma multiforme treatment.
 
As part of the agreement, Germany’s Merck also gained a worldwide, non-exclusive license to use the results from the methylation assay for optimizing cilengitide treatment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."